Adamis Pharmaceuticals Corporation (ADMP)

NASDAQ: ADMP · Delayed Price · USD
0.610
-0.024 (-3.71%)
At close: Jan 14, 2022 4:00 PM
0.623
0.013 (2.065%)
After-hours:Jan 14, 2022 7:59 PM EST

Company Description

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States.

The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose.

It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19.

In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals.

Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.

Adamis Pharmaceuticals Corporation
CountryUnited States
IndustryPharmaceuticals
SectorHealth Care
Employees116
CEODennis Carlo

Contact Details

Address:
11682 El Camino Real Ste 300
San Diego, California 92130
United States
Phone858 997 2400
Websiteadamispharmaceuticals.com

Stock Details

Ticker SymbolADMP
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0000887247

Key Executives

NamePosition
Dr. Dennis J. CarloPresident, Chief Executive Officer and Director
David J. MarguglioSenior Vice President, Chief Business Officer and Director
Dr. Ronald B. MossChief Medical Officer
David C. BenedictoChief Financial Officer
Karen K. DanielsVice President of Operations
Mark FlatherSenior Director of Investor Relations and Corporate Communications
Jennifer C. SuskiSenior Director of Marketing
Eddie Wabern GloverChief Executive Officer of US Compounding Inc
Robert B. RothermelConsultant

Latest SEC Filings

DateTypeTitle
Jan 10, 20228-KCurrent report
Jan 4, 20228-KCurrent report
Dec 3, 20214Statement of changes in beneficial ownership of securities
Dec 3, 20214Statement of changes in beneficial ownership of securities
Dec 3, 20214Statement of changes in beneficial ownership of securities
Dec 3, 20214Statement of changes in beneficial ownership of securities
Nov 23, 20218-KCurrent report
Nov 22, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 22, 20218-KCurrent report
Nov 22, 202110-QQuarterly report [Sections 13 or 15(d)]
View All SEC Filings